Cote d'Ivoire vs South Korea: The number of people with susceptibility test result for rifampicin
Cote d'Ivoire
8,494
in 2021
South Korea
9,284
in 2021
Cote d'Ivoire rank
25th
South Korea rank
22nd
The number of people with susceptibility test result for rifampicin over time
- Cote d'Ivoire
- South Korea
How they compare
South Korea currently reports 9,284 against 8,494 in Cote d'Ivoire, a difference of 790.
That makes South Korea's figure about 1.1 times Cote d'Ivoire's.
Across all 5 years both countries report, South Korea has been ahead every year.
Cote d'Ivoire ranks 25th and South Korea ranks 22nd of 155 countries.
South Korea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cote d'Ivoire | South Korea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,175 | 13,475 | 10,300 | South Korea |
| 2020s | 4,890 | 9,936 | 5,047 | South Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Cote d'Ivoire or South Korea?
- South Korea, at 9,284 against 8,494 in Cote d'Ivoire as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Cote d'Ivoire and South Korea?
- 790, with South Korea ahead.
- How many years of comparable data are there for Cote d'Ivoire and South Korea?
- 5 years are reported by both, from 2017 to 2021.
- How do Cote d'Ivoire and South Korea rank globally for the number of people with susceptibility test result for rifampicin?
- Cote d'Ivoire ranks 25th and South Korea ranks 22nd of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.